Skip to content

US · EPRX · BIOTECHNOLOGY

Eupraxia Pharmaceuticals Inc. (EPRX) intrinsic value and stock valuation

$5.80as of 2026-11-21 · Mkt cap 226.66M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Eupraxia Pharmaceuticals Inc. DCF and intrinsic value

InvestorsCraft values EPRX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from EPRX’s statements →

Eupraxia Pharmaceuticals Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Victoria, BC V8R 5G4 eupraxiapharma.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$0.00
20172025
Net income
-$-53.86M
20172025
Free cash flow
-$-29.63M
20172025
Total equity
$80.5M
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-53.66M-$-26.99M-$-20.97M-$-17.62M-$-14.65M
Net income-$-53.86M-$-25.49M-$-21.25M-$-18.49M-$-18.03M
EPSd-$-1.35M-$-751.25K-$-879.92K-$-958.53K-$-1.27M
Operating cash flow-$-29.03M-$-29.99M-$-15.62M-$-14.4M-$-11.58M
Capital expenditure-$-600K-$-100K-$-60K-$-240K-$-340K
Free cash flow-$-29.63M-$-30.1M-$-15.68M-$-14.63M-$-11.92M
Total assets$86.2M$34.9M$15.3M$25.9M$31.2M
Total debt$150K$70K$7.87M$12.2M$9.99M
Net debt-$-80.41M-$-33.03M-$-6.69M-$-12.56M-$-10.9M
Total equity$80.5M$31.8M$670K$9.76M$19.1M
Cash and short-term investments$80.6M$33.1M$14.6M$24.7M$29.9M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$330K$160K$0.00$0.00$110K
Gross profit-$-330K-$-160K$0.00$0.00-$-110K
Research and development expenses$29.5M$16.1M$15.3M$13.6M$7.59M
Selling, general and administrative expenses$17.1M$10.9M$5.63M$3.99M$6.97M
Other expenses$6.72M$0.00$0.00$0.00$3.93M
Operating expenses$53.3M$27M$21M$17.6M$18.5M
Cost and expenses$53.7M$27M$21M$17.6M$14.7M
Interest income$1.41M$1.16M$650K$430K$50K
Interest expense$0.00$600K$880K$980K$1.02M
Depreciation and amortization$330K$170K$120K$150K$90K
Ebitda-$-53.33M-$-24.95M-$-20.78M-$-17.86M-$-17.22M
Operating income-$-53.66M-$-26.99M-$-20.97M-$-17.62M-$-14.65M
Total other income/expenses, net-$-210K$1.26M-$-810K-$-1.37M-$-3.68M
Income before tax-$-53.87M-$-25.73M-$-21.78M-$-18.99M-$-18.33M
Income tax expense$30K$0.00$30K$0.00$0.00
Net income-$-53.86M-$-25.49M-$-21.25M-$-18.49M-$-18.03M
Weighted average shares outstanding$40M$33.9M$24.2M$19.3M$14.2M
Weighted average diluted shares outstanding$40M$33.9M$24.2M$19.3M$14.2M
Balance sheet
20252024202320222021
Cash and short-term investments$80.6M$33.1M$14.6M$24.7M$29.9M
Net receivables$670K$230K$140K$0.00$430K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$85.1M$34.4M$14.9M$25.2M$30.6M
Property, plant and equipment, net$990K$420K$340K$720K$590K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$1.05M$510K$350K$720K$620K
Total assets$86.2M$34.9M$15.3M$25.9M$31.2M
Accounts payable$0.00$0.00$0.00$0.00$0.00
Short-term debt$80K$70K$7.87M$180K$150K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$5.63M$3.1M$14.6M$4.14M$2.27M
Long-term debt$80K$0.00$0.00$12M$9.84M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$80K$0.00$0.00$12M$9.84M
Capital lease obligations$150K$70K$40K$140K$200K
Total liabilities$5.7M$3.1M$14.6M$16.1M$12.1M
Common stock$195.4M$116.4M$70M$96.1M$81.3M
Retained earnings-$-169.58M-$-131M-$-79.43M-$-104.63M-$-74.75M
Accumulated other comprehensive income (loss)-$-2.04M-$-4.16M-$-2.04M-$-3.77M$0.00
Total equity$80.5M$31.8M$670K$9.76M$19.1M
Total investments$0.00$0.00$0.00$0.00$9.01M
Total debt$150K$70K$7.87M$12.2M$9.99M
Net debt-$-80.41M-$-33.03M-$-6.69M-$-12.56M-$-10.9M
Cash flow statement
20252024202320222021
Net income-$-39.22M-$-25.74M-$-21.81M-$-18.99M-$-18.18M
Depreciation and amortization$240K$170K$120K$150K$90K
Stock-based compensation$0.00$3.22M$1.06M$1.43M$0.00
Change in working capital-$-730K-$-6.76M$4.03M$1.51M-$-170K
Accounts receivable-$-440K-$-100K-$-80K$230K$150K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$2.4M-$-710K$440K$1.32M$0.00
Net cash provided by operating activities-$-29.03M-$-29.99M-$-15.62M-$-14.4M-$-11.58M
Investments in property, plant and equipment-$-600K-$-100K-$-60K-$-240K-$-340K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-600K-$-80K-$-60K$9.83M-$-11.42M
Common stock issued$77.3M$54.6M$12M$10.6M$29.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$77.3M$45.8M$15.9M$10.8M$39.5M
Net change in cash$47.3M$13.8M$810K$5.73M$16.4M
Cash at end of period$80.4M$33.1M$14.6M$18.3M$16.5M
Operating cash flow-$-29.03M-$-29.99M-$-15.62M-$-14.4M-$-11.58M
Capital expenditure-$-600K-$-100K-$-60K-$-240K-$-340K
Free cash flow-$-29.63M-$-30.1M-$-15.68M-$-14.63M-$-11.92M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Eupraxia Pharmaceuticals Inc.

        Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

        CEO
        James A. Helliwell
        Employees
        49
        Beta
        1.50

        Explore

        Frequently asked questions

        What is the intrinsic value of Eupraxia Pharmaceuticals Inc. (EPRX)?

        InvestorsCraft does not currently publish an intrinsic value for EPRX. How the IC value is calculated.

        Is EPRX undervalued?

        InvestorsCraft does not publish an undervaluation signal for EPRX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.